BeOne Medicines (FRA:49BA) Cyclically Adjusted FCF per Share: €-8.82 (As of Mar. 2026)


FRA:49BA BeOne Medicines Ltd FRA:49BA
77 GF Score
Price €258.00
GF Value €318.05
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BeOne Medicines Cyclically Adjusted FCF per Share?

BeOne Medicines FRA:49BA -1.53% 77 Cyclically Adjusted FCF per Share is €-8.82 as of Mar. 2026. GuruFocus rates FRA:49BA with a GF Score™ of 77/100 and a GF Value™ of €318.05 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

BeOne Medicines's adjusted free cash flow per share for the three months ended in Mar. 2026 was €1.200. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-8.82 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-13), BeOne Medicines's current stock price is €258.00. BeOne Medicines's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-8.82. BeOne Medicines's Cyclically Adjusted Price-to-FCF of today is .


BeOne Medicines  (FRA:49BA) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


BeOne Medicines Cyclically Adjusted FCF per Share Related Terms


BeOne Medicines Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for BeOne Medicines's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeOne Medicines Cyclically Adjusted FCF per Share Chart

BeOne Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -10.78 -9.10

BeOne Medicines Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.66 -9.92 -9.38 -9.10 -8.82

FRA:49BA vs MRNA, RPRX, ROIV: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, BeOne Medicines's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BeOne Medicines Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeOne Medicines's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BeOne Medicines's Cyclically Adjusted Price-to-FCF falls into.


FRA:49BA
77GF Score
BeOne Medicines Ltd FRA:49BA
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BeOne Medicines Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BeOne Medicines's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.2/108.0600*108.0600
=1.200

Current CPI (Mar. 2026) = 108.0600.

BeOne Medicines Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.668 100.088 -0.721
201609 -0.838 99.604 -0.909
201612 -0.908 99.380 -0.987
201703 -1.014 100.040 -1.095
201706 -1.464 100.285 -1.577
201709 -0.221 100.254 -0.238
201712 1.391 100.213 1.500
201803 -1.953 100.836 -2.093
201806 -2.035 101.435 -2.168
201809 -2.396 101.246 -2.557
201812 -4.104 100.906 -4.395
201903 -3.309 101.571 -3.520
201906 -1.295 102.044 -1.371
201909 -4.469 101.396 -4.763
201912 -4.488 101.063 -4.799
202003 -4.757 101.048 -5.087
202006 -3.377 100.743 -3.622
202009 -4.048 100.585 -4.349
202012 -3.500 100.241 -3.773
202103 0.644 100.800 0.690
202106 -4.146 101.352 -4.420
202109 -5.156 101.533 -5.487
202112 -6.203 101.776 -6.586
202203 -3.161 103.205 -3.310
202206 -3.959 104.783 -4.083
202209 -6.740 104.835 -6.947
202212 -4.441 104.666 -4.585
202303 -6.181 106.245 -6.287
202306 -3.664 106.576 -3.715
202309 -2.282 106.570 -2.314
202312 -3.424 106.461 -3.475
202403 -4.426 107.355 -4.455
202406 -1.824 107.991 -1.825
202409 0.465 107.468 0.468
202412 -0.155 107.128 -0.156
202503 -0.602 107.722 -0.604
202506 1.539 108.075 1.539
202509 2.632 107.710 2.641
202512 2.806 107.200 2.829
202603 1.200 108.060 1.200

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-8.82 mean?
BeOne Medicines (FRA:49BA) has a Cyclically Adjusted FCF per Share of €-8.82 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on BeOne Medicines and its competitors.
Is BeOne Medicines' Cyclically Adjusted FCF per Share too high?
BeOne Medicines' current Cyclically Adjusted FCF per Share is €-8.82. Overall, BeOne Medicines has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Cyclically Adjusted FCF per Share compare to MRNA and RPRX?
BeOne Medicines' Cyclically Adjusted FCF per Share of €-8.82 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on BeOne Medicines and its competitors. BeOne Medicines's current Cyclically Adjusted FCF per Share is €-8.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (FRA:49BA) is currently considered Modestly Undervalued. The stock's GF Value™ is €318.05, compared to a current price of €258.00 — trading 18.9% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €-8.82. BeOne Medicines' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For BeOne Medicines (FRA:49BA), the current Cyclically Adjusted FCF per Share is €-8.82 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BeOne Medicines (FRA:49BA) Overvalued in 2026?

Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued. The current stock price of €258.00 is trading 18.9% below its estimated GF Value™ of €318.05. GuruFocus considers BeOne Medicines to be Modestly Undervalued.

Key valuation signals for FRA:49BA:

  • Cyclically Adjusted FCF per Share: €-8.82
  • GF Value™: €318.05 vs. price of €258.00 (18.9% below fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the FRA:49BA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BeOne Medicines Business Description

Address c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
77GF Score

Get the complete analysis for FRA:49BA

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€258.00
Price
€318.05
GF Value